Plexbio/Genemed Biotechnologies, Inc.

Corporate Overview PlexBio Co., Ltd. was established in May 2010 to design, develop and manufacture IVD products and instrumentations in ISO-certified facilities. To this date, PlexBio has expanded from Asia headquarters in Taipei, Taiwan to Jiangsu Province, China, and has a U.S research facility in San Francisco. In order to address the issue of rising healthcare costs and an increasing range of available tests, it is crucial for clinical and research labs to consider the cost of labor, sample volume, time and maintenance when it comes to assay formats. Therefore, PlexBio aims to provide a cutting-edge multiplexing platform using our patented Precision Image Code (πCode) MicroDisc technology to overcome this limitation. Our πCode Microdisc technology is currently the largest multiplexing platform, capable of generating approximately 16,000 circular image patterns. Each image pattern corresponds to an individual target and can be detected simultaneously via advanced optical imaging and fluorescence analyzers. By using our multiplexing platform, we are able to offer highly sensitive and specific results with low sample volumes, which saves time and labor. Currently, PlexBio is researching and developing high-quality reagents focusing on companion diagnostics, early cancer detection and prenatal diagnostics with ultra-detection sensitivity and fully automated diagnostics instruments for high-throughput clinical needs. With our innovative technologies, PlexBio intends to revolutionize the IVD industry developments, placing PlexBio as the leading brand of global IVD market.